(Q53142244)

11 May 2018

title

Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. (English)

1 reference

11 May 2018

author name string

Noriyuki Akutsu

1

1 reference

11 May 2018

Shigeru Sasaki

2

1 reference

11 May 2018

Hideyasu Takagi

3

1 reference

11 May 2018

Masayo Motoya

4

1 reference

11 May 2018

Masahiro Shitani

5

1 reference

11 May 2018

Mai Igarashi

6

1 reference

11 May 2018

Daisuke Hirayama

7

1 reference

11 May 2018

Hideki Wakasugi

8

1 reference

11 May 2018

Hiroyuki Yamamoto

9

1 reference

11 May 2018

Hiroyuki Kaneto

10

1 reference

11 May 2018

Kazuhiko Yonezawa

11

1 reference

11 May 2018

Atsushi Yawata

12

1 reference

11 May 2018

Takeya Adachi

13

1 reference

11 May 2018

Yasuo Hamamoto

14

1 reference

11 May 2018

Yasuhisa Shinomura

15

1 reference

11 May 2018

publication date

18 April 2014

1 reference

11 May 2018

International Journal of Clinical Oncology

published in

1 reference

11 May 2018

volume

20

1 reference

11 May 2018

issue

1

1 reference

11 May 2018

page(s)

105-110

1 reference

11 May 2018

https://scigraph.springernature.com/pub.10.1007/s10147-014-0691-5

exact match

0 references

cites work

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuita

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Rapid development of hypertension by sorafenib: toxicity or target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-014-0691-5

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

21 January 2018

1 reference

12 December 2020

Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients

1 reference

12 December 2020

Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib

1 reference

12 December 2020

Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines

1 reference

12 December 2020

Hypertension as a predictive factor of Sunitinib activity

1 reference

12 December 2020

10.1007/S10147-014-0691-5

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018